SEC Form 4 · accession 0001193125-26-262292
Climb Bio, Inc. · CLYM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew David Levin
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 8, 2026 · 6:42 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001768446
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $10.55 | Jun 5, 2026 | A | 40,000 | A | — | Jun 4, 2036 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
- F2Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.